Opus Genetics' Joseph K. Schachle sells 4,767 shares

The automatic sale met tax withholding obligations tied to the vesting and settlement of restricted stock units, rather than reflecting a discretionary trade.

Rhea-AI Filing Summary

Opus Genetics, Inc. Chief Operating Officer Joseph K. Schachle reported a sale of 4,767 common shares at $3.5650 per share on October 23, 2026. The shares were sold automatically on his behalf, as required by the issuer to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units; the transaction was not discretionary. Schachle reported direct holdings of 286,673 shares after the sale.

Insider Trade Summary

Net Seller: 4,767 shares

Net Sell 1 txn

Insider SCHACHLE JOSEPH K

Role Chief Operating Officer

Sold 4,767 shs ($17K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	4,767	$3.565	$17K

Holdings After Transaction: Common Stock — 286,673 shares (Direct)

Footnotes (1)

1. F1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units. This transaction does not represent a discretionary trade by the Reporting Person.

Key Figures

Shares sold: 4,767 shares Sale price: $3.5650 per share Direct holdings after sale: 286,673 shares

3 metrics

Shares sold 4,767 shares October 23, 2026

Sale price $3.5650 per share October 23, 2026

Direct holdings after sale 286,673 shares After the October 23, 2026 transaction

Key Terms

restricted stock units, tax withholding obligations, discretionary trade

3 terms

restricted stock units financial

"the vesting and settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"to satisfy tax withholding obligations"

discretionary trade financial

"does not represent a discretionary trade"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Opus Genetics COO Joseph K. Schachle sell?

Joseph K. Schachle reported selling 4,767 common shares at $3.5650 per share on October 23, 2026. He reported direct holdings of 286,673 shares after the sale. No Rule 10b5-1 plan is reported.

Why did Opus Genetics COO Joseph K. Schachle's shares sell?

The 4,767 shares were sold automatically on behalf of Joseph K. Schachle, as required by Opus Genetics to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. The transaction was not discretionary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 04:48 PM EDT Accepted by SEC EDGAR 10/27/2026 - 04:47 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHACHLE JOSEPH K

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/23/2026		S(1)		4,767	D	$3.565	286,673	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units. This transaction does not represent a discretionary trade by the Reporting Person.

	/s/ Amy Rabourn, by Power of Attorney	10/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)